Jacob Painter
Concepts (203)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Analgesics, Opioid | 21 | 2024 | 557 | 3.820 |
Why?
| Neuralgia | 3 | 2023 | 63 | 2.290 |
Why?
| Veterans | 8 | 2024 | 560 | 1.950 |
Why?
| Breast Neoplasms | 4 | 2023 | 1179 | 1.710 |
Why?
| Chronic Pain | 9 | 2024 | 166 | 1.680 |
Why?
| Antipsychotic Agents | 2 | 2018 | 232 | 1.020 |
Why?
| Respiratory Insufficiency | 2 | 2023 | 113 | 0.980 |
Why?
| Pain | 5 | 2022 | 381 | 0.970 |
Why?
| Evidence-Based Practice | 3 | 2023 | 96 | 0.960 |
Why?
| Drug Overdose | 4 | 2022 | 163 | 0.950 |
Why?
| United States | 21 | 2024 | 4874 | 0.910 |
Why?
| Humans | 57 | 2024 | 50208 | 0.890 |
Why?
| Retrospective Studies | 21 | 2024 | 6134 | 0.890 |
Why?
| Fibromyalgia | 2 | 2013 | 17 | 0.870 |
Why?
| Hydroxyurea | 1 | 2022 | 30 | 0.840 |
Why?
| Anemia, Sickle Cell | 1 | 2022 | 96 | 0.780 |
Why?
| Cost-Benefit Analysis | 4 | 2024 | 273 | 0.740 |
Why?
| Aged | 18 | 2023 | 9405 | 0.730 |
Why?
| Cyclohexanecarboxylic Acids | 1 | 2020 | 18 | 0.730 |
Why?
| Inappropriate Prescribing | 2 | 2017 | 18 | 0.700 |
Why?
| Critical Illness | 4 | 2021 | 288 | 0.700 |
Why?
| Diabetes Mellitus, Type 2 | 2 | 2024 | 486 | 0.700 |
Why?
| United States Department of Veterans Affairs | 7 | 2024 | 288 | 0.690 |
Why?
| Pharmacists | 2 | 2018 | 144 | 0.680 |
Why?
| Students, Pharmacy | 2 | 2018 | 121 | 0.680 |
Why?
| Opioid-Related Disorders | 5 | 2023 | 384 | 0.670 |
Why?
| Lymphedema | 1 | 2019 | 43 | 0.660 |
Why?
| Female | 28 | 2024 | 26635 | 0.660 |
Why?
| Calcium Channel Blockers | 1 | 2019 | 63 | 0.660 |
Why?
| Guidelines as Topic | 1 | 2019 | 111 | 0.650 |
Why?
| Tramadol | 3 | 2024 | 30 | 0.630 |
Why?
| Program Evaluation | 5 | 2024 | 354 | 0.610 |
Why?
| Serotonin Syndrome | 1 | 2018 | 6 | 0.610 |
Why?
| Medicare | 4 | 2023 | 249 | 0.610 |
Why?
| Case-Control Studies | 4 | 2023 | 1126 | 0.610 |
Why?
| Adult | 22 | 2024 | 13324 | 0.610 |
Why?
| Intensive Care Units | 4 | 2021 | 222 | 0.610 |
Why?
| Stress Disorders, Post-Traumatic | 3 | 2024 | 365 | 0.610 |
Why?
| Psychotherapy | 2 | 2024 | 106 | 0.610 |
Why?
| Vasopressins | 4 | 2019 | 39 | 0.590 |
Why?
| Benzodiazepines | 1 | 2018 | 73 | 0.590 |
Why?
| Shock, Septic | 4 | 2021 | 78 | 0.590 |
Why?
| Seizures | 1 | 2019 | 196 | 0.580 |
Why?
| Middle Aged | 19 | 2024 | 12206 | 0.580 |
Why?
| Etomidate | 1 | 2016 | 5 | 0.570 |
Why?
| Off-Label Use | 1 | 2017 | 25 | 0.570 |
Why?
| Vasoconstrictor Agents | 4 | 2019 | 84 | 0.570 |
Why?
| Cannabis | 1 | 2019 | 145 | 0.570 |
Why?
| Phenols | 1 | 2018 | 80 | 0.570 |
Why?
| Anesthetics, Intravenous | 1 | 2016 | 24 | 0.560 |
Why?
| Pneumonia, Ventilator-Associated | 1 | 2016 | 19 | 0.560 |
Why?
| Cohort Studies | 7 | 2022 | 1422 | 0.560 |
Why?
| Hyperalgesia | 1 | 2017 | 56 | 0.560 |
Why?
| Community Pharmacy Services | 1 | 2018 | 67 | 0.550 |
Why?
| Curriculum | 2 | 2024 | 400 | 0.550 |
Why?
| Depression | 3 | 2022 | 570 | 0.540 |
Why?
| Smoking Cessation | 1 | 2019 | 300 | 0.530 |
Why?
| Mental Disorders | 2 | 2018 | 395 | 0.530 |
Why?
| HIV Infections | 2 | 2016 | 357 | 0.500 |
Why?
| Male | 25 | 2024 | 25399 | 0.490 |
Why?
| Mental Health Services | 1 | 2017 | 199 | 0.480 |
Why?
| Patient Acceptance of Health Care | 1 | 2018 | 328 | 0.480 |
Why?
| Aged, 80 and over | 7 | 2023 | 3154 | 0.480 |
Why?
| Telemedicine | 2 | 2017 | 449 | 0.470 |
Why?
| Respiration, Artificial | 1 | 2016 | 274 | 0.470 |
Why?
| Ambulatory Care | 1 | 2015 | 222 | 0.470 |
Why?
| Pain Management | 6 | 2023 | 162 | 0.440 |
Why?
| Norepinephrine | 3 | 2018 | 113 | 0.430 |
Why?
| Geography | 1 | 2013 | 60 | 0.430 |
Why?
| Cooperative Behavior | 3 | 2018 | 227 | 0.390 |
Why?
| Analgesics | 2 | 2023 | 101 | 0.370 |
Why?
| Neoplasms | 1 | 2019 | 1249 | 0.340 |
Why?
| Palliative Care | 2 | 2020 | 186 | 0.300 |
Why?
| Education, Pharmacy, Graduate | 2 | 2018 | 19 | 0.300 |
Why?
| Viscosupplements | 2 | 2017 | 14 | 0.290 |
Why?
| Hyaluronic Acid | 2 | 2017 | 34 | 0.290 |
Why?
| Time Factors | 6 | 2018 | 2922 | 0.280 |
Why?
| Propensity Score | 3 | 2022 | 122 | 0.270 |
Why?
| Vancomycin | 2 | 2018 | 81 | 0.270 |
Why?
| Osteoarthritis, Knee | 2 | 2017 | 88 | 0.270 |
Why?
| Acute Kidney Injury | 2 | 2021 | 285 | 0.250 |
Why?
| Risk Factors | 4 | 2021 | 3629 | 0.230 |
Why?
| Emergency Service, Hospital | 2 | 2019 | 484 | 0.230 |
Why?
| Prevalence | 3 | 2022 | 951 | 0.220 |
Why?
| Pharmaceutical Services | 1 | 2024 | 54 | 0.220 |
Why?
| Vaccines | 1 | 2023 | 50 | 0.210 |
Why?
| Advance Care Planning | 1 | 2023 | 19 | 0.210 |
Why?
| Pharmacy | 1 | 2024 | 57 | 0.210 |
Why?
| Randomized Controlled Trials as Topic | 3 | 2024 | 550 | 0.210 |
Why?
| SEER Program | 1 | 2023 | 92 | 0.210 |
Why?
| Pharmacies | 1 | 2023 | 61 | 0.210 |
Why?
| Developmental Disabilities | 1 | 2023 | 119 | 0.210 |
Why?
| Intellectual Disability | 1 | 2023 | 124 | 0.200 |
Why?
| Guideline Adherence | 1 | 2023 | 133 | 0.200 |
Why?
| Quality Improvement | 1 | 2023 | 209 | 0.200 |
Why?
| Health Care Costs | 1 | 2022 | 170 | 0.190 |
Why?
| Neck Pain | 1 | 2021 | 10 | 0.190 |
Why?
| Carcinoma, Non-Small-Cell Lung | 1 | 2023 | 154 | 0.190 |
Why?
| Education, Pharmacy | 1 | 2024 | 143 | 0.190 |
Why?
| Back Pain | 1 | 2021 | 39 | 0.190 |
Why?
| Arthralgia | 1 | 2021 | 43 | 0.190 |
Why?
| Drug Prescriptions | 2 | 2021 | 97 | 0.190 |
Why?
| Buprenorphine | 1 | 2023 | 139 | 0.190 |
Why?
| Professional-Patient Relations | 1 | 2021 | 47 | 0.190 |
Why?
| Anti-Infective Agents | 1 | 2021 | 95 | 0.190 |
Why?
| Gastrointestinal Hemorrhage | 1 | 2021 | 79 | 0.190 |
Why?
| Morphine | 1 | 2021 | 103 | 0.180 |
Why?
| Bacteremia | 1 | 2021 | 92 | 0.180 |
Why?
| Afghan Campaign 2001- | 2 | 2018 | 40 | 0.180 |
Why?
| Amines | 1 | 2020 | 41 | 0.180 |
Why?
| Drug Monitoring | 2 | 2018 | 78 | 0.180 |
Why?
| Professional Role | 2 | 2018 | 76 | 0.180 |
Why?
| Brain Neoplasms | 1 | 2023 | 288 | 0.170 |
Why?
| Outpatients | 1 | 2020 | 112 | 0.170 |
Why?
| Primary Health Care | 2 | 2024 | 360 | 0.170 |
Why?
| Rural Population | 1 | 2024 | 537 | 0.170 |
Why?
| Health Promotion | 1 | 2022 | 267 | 0.170 |
Why?
| Hydrocodone | 3 | 2024 | 20 | 0.170 |
Why?
| Oxycodone | 3 | 2024 | 27 | 0.160 |
Why?
| Young Adult | 2 | 2019 | 3981 | 0.160 |
Why?
| Treatment Outcome | 6 | 2024 | 5155 | 0.160 |
Why?
| Critical Care | 2 | 2018 | 213 | 0.160 |
Why?
| Drug Therapy, Combination | 2 | 2018 | 381 | 0.160 |
Why?
| Motivation | 2 | 2018 | 273 | 0.160 |
Why?
| Anti-Bacterial Agents | 3 | 2021 | 747 | 0.160 |
Why?
| Sepsis | 1 | 2021 | 221 | 0.160 |
Why?
| Hematologic Tests | 1 | 2018 | 10 | 0.150 |
Why?
| Hypotension | 1 | 2019 | 63 | 0.150 |
Why?
| Age Distribution | 1 | 2018 | 168 | 0.150 |
Why?
| Physicians, Primary Care | 1 | 2018 | 43 | 0.150 |
Why?
| Lung Neoplasms | 1 | 2023 | 605 | 0.150 |
Why?
| Drug Interactions | 1 | 2018 | 208 | 0.150 |
Why?
| Career Mobility | 1 | 2017 | 28 | 0.140 |
Why?
| Adolescent | 2 | 2019 | 6390 | 0.140 |
Why?
| Bacterial Infections | 1 | 2018 | 96 | 0.140 |
Why?
| Drug Utilization | 1 | 2017 | 77 | 0.140 |
Why?
| Adrenal Cortex Hormones | 1 | 2017 | 94 | 0.140 |
Why?
| Logistic Models | 1 | 2019 | 889 | 0.140 |
Why?
| Odds Ratio | 1 | 2018 | 546 | 0.140 |
Why?
| Penicillanic Acid | 1 | 2016 | 20 | 0.130 |
Why?
| Arthroplasty, Replacement, Knee | 2 | 2017 | 284 | 0.130 |
Why?
| Cephalosporins | 1 | 2016 | 41 | 0.130 |
Why?
| Counseling | 1 | 2016 | 132 | 0.130 |
Why?
| Evidence-Based Medicine | 1 | 2017 | 247 | 0.130 |
Why?
| Prospective Studies | 2 | 2018 | 2379 | 0.130 |
Why?
| Delivery of Health Care | 1 | 2018 | 310 | 0.120 |
Why?
| Patient Care Team | 1 | 2016 | 257 | 0.120 |
Why?
| Pharmacy Service, Hospital | 1 | 2014 | 16 | 0.120 |
Why?
| Prescription Drug Misuse | 1 | 2014 | 34 | 0.120 |
Why?
| Comparative Effectiveness Research | 2 | 2024 | 44 | 0.120 |
Why?
| Depressive Disorder | 1 | 2016 | 339 | 0.120 |
Why?
| Community Health Services | 1 | 2014 | 101 | 0.110 |
Why?
| Obesity | 1 | 2022 | 1108 | 0.110 |
Why?
| Length of Stay | 1 | 2016 | 621 | 0.110 |
Why?
| Drug Utilization Review | 1 | 2013 | 23 | 0.110 |
Why?
| Drug Administration Schedule | 3 | 2018 | 377 | 0.100 |
Why?
| Hospitalization | 1 | 2016 | 655 | 0.100 |
Why?
| Arkansas | 3 | 2022 | 1985 | 0.090 |
Why?
| Arterial Pressure | 2 | 2018 | 43 | 0.070 |
Why?
| Organ Dysfunction Scores | 2 | 2017 | 17 | 0.070 |
Why?
| Injections, Intra-Articular | 2 | 2017 | 33 | 0.070 |
Why?
| Orthopedic Procedures | 2 | 2017 | 68 | 0.070 |
Why?
| Knee Joint | 2 | 2017 | 162 | 0.070 |
Why?
| Follow-Up Studies | 2 | 2024 | 2190 | 0.060 |
Why?
| Implosive Therapy | 1 | 2024 | 17 | 0.060 |
Why?
| Incidence | 2 | 2019 | 1006 | 0.060 |
Why?
| Antidepressive Agents | 1 | 2024 | 176 | 0.050 |
Why?
| Advance Directives | 1 | 2023 | 29 | 0.050 |
Why?
| Food Supply | 1 | 2024 | 91 | 0.050 |
Why?
| Veterans Health | 1 | 2023 | 62 | 0.050 |
Why?
| Activities of Daily Living | 1 | 2023 | 173 | 0.050 |
Why?
| Combined Modality Therapy | 1 | 2024 | 636 | 0.050 |
Why?
| Learning | 1 | 2024 | 159 | 0.050 |
Why?
| Staphylococcus | 1 | 2021 | 35 | 0.050 |
Why?
| Animals | 1 | 2017 | 13246 | 0.050 |
Why?
| Infusions, Intravenous | 1 | 2021 | 213 | 0.050 |
Why?
| Body Mass Index | 1 | 2024 | 656 | 0.050 |
Why?
| Patient Education as Topic | 1 | 2024 | 313 | 0.050 |
Why?
| Child | 2 | 2023 | 6851 | 0.050 |
Why?
| Epidemics | 1 | 2018 | 19 | 0.040 |
Why?
| Inservice Training | 1 | 2018 | 30 | 0.040 |
Why?
| History, 21st Century | 1 | 2018 | 55 | 0.040 |
Why?
| Medicaid | 1 | 2021 | 257 | 0.040 |
Why?
| History, 20th Century | 1 | 2018 | 99 | 0.040 |
Why?
| Education, Nursing, Continuing | 1 | 2018 | 19 | 0.040 |
Why?
| Physicians | 1 | 2021 | 230 | 0.040 |
Why?
| Pharmacoepidemiology | 1 | 2017 | 8 | 0.040 |
Why?
| Molecular Weight | 1 | 2017 | 85 | 0.040 |
Why?
| Academic Medical Centers | 1 | 2018 | 147 | 0.040 |
Why?
| Statistics, Nonparametric | 1 | 2017 | 193 | 0.040 |
Why?
| Schools, Pharmacy | 1 | 2017 | 54 | 0.030 |
Why?
| Physician-Patient Relations | 1 | 2018 | 141 | 0.030 |
Why?
| Research Design | 1 | 2018 | 342 | 0.030 |
Why?
| Piperacillin | 1 | 2016 | 23 | 0.030 |
Why?
| Pain Measurement | 1 | 2017 | 240 | 0.030 |
Why?
| Kaplan-Meier Estimate | 1 | 2017 | 465 | 0.030 |
Why?
| Interviews as Topic | 1 | 2016 | 259 | 0.030 |
Why?
| Depressive Disorder, Major | 1 | 2017 | 151 | 0.030 |
Why?
| Geriatrics | 1 | 2016 | 46 | 0.030 |
Why?
| Comorbidity | 1 | 2017 | 613 | 0.030 |
Why?
| Patient Satisfaction | 1 | 2016 | 275 | 0.030 |
Why?
| Societies, Medical | 1 | 2016 | 177 | 0.030 |
Why?
| Substance Abuse Detection | 1 | 2014 | 92 | 0.030 |
Why?
|
|
Painter's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|